The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 02, 2015

Filed:

Nov. 07, 2011
Applicants:

John C. Byrd, Columbus, OH (US);

Amy J. Johnson, Columbus, OH (US);

Emilia Mahoney, Columbus, OH (US);

David M. Lucas, Hilliard, OH (US);

Michael R. Grever, Powell, OH (US);

Inventors:

John C. Byrd, Columbus, OH (US);

Amy J. Johnson, Columbus, OH (US);

Emilia Mahoney, Columbus, OH (US);

David M. Lucas, Hilliard, OH (US);

Michael R. Grever, Powell, OH (US);

Assignee:

The Ohio State University, Columbus, OH (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C12N 9/99 (2006.01); A61K 31/4706 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); A61K 31/343 (2006.01); A61K 31/453 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4706 (2013.01); G01N 33/57426 (2013.01); G01N 2800/52 (2013.01); A61K 45/06 (2013.01); A61K 31/343 (2013.01); A61K 31/453 (2013.01); A61K 48/005 (2013.01);
Abstract

A method of (a) treating a lymphoproliferative disease in a subject in need thereof; (b) slowing the progression of lymphoproliferative disease in a subject who has been diagnosed with a lymphoproliferative disease; or (c) preventing or delaying development of a lymphoproliferative disease in a subject who is at risk of developing a lymphoproliferative disease. The method generally comprises administering to the individual an effective amount of a combination therapy comprising: i) at least one autophagy modulating agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof; and ii) at least one CDK inhibitor agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof, wherein the i) agent and the ii) agents are administered in amounts sufficient to enhance the cytotoxicity of the combination relative to the CDK inhibitor agent treatment alone.


Find Patent Forward Citations

Loading…